Risk factors
Genprex (GNPX) risk factors
Item 1A of every Genprex, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors75 risks1 new1 dropped10 reworded
Genprex relies heavily on ongoing equity sales under its ATM agreement to fund operations into the second quarter of 2027.
Filed Mar 30, 2026 - FY2024 10-K risk factors75 risks
Genprex faces going concern doubts with an accumulated deficit of approximately $154.8 million as of December 31, 2024. The business relies heavily on the clinical success of lead drug REQORSA and preclinical candidate GPX-002. Operations depend entirely on third-party CDMOs for manufacturing and CROs for clinical trial execution.
Filed Apr 01, 2025